SCHEMBL2896547

SCHEMBL2896547

CC(C)n1c(=O)c(O)c2n(c1=O)CCN(Cc1ccccc1C#N)C2=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CLPP Q16740 1/20 0.40
DPP4 P27487 3/20 0.39
NOX4 Q9NPH5 1/20 0.39
KMT2A Q03164 1/20 0.39
COMT P21964 1/20 0.38
BRD4 O60885 1/20 0.38
TSHR P16473 1/20 0.38
EGLN3 Q9H6Z9 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
TACR1 P25103 2/20 0.37
FEN1 P39748 1/20 0.37
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
CYP19A1 P11511 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2894894 0.82 PSEN1 (0.46) KMT2ATSHRALDH1A1NPSR1HCRTR2
SCHEMBL2899829 0.76 HRH3 (0.47) KMT2ATSHRSIRT1FEN1ALDH1A1
SCHEMBL2895523 0.74 P2RX7 (0.51) KMT2AALDH1A1
SCHEMBL2895650 0.69 MAOB (0.38) CLPPTSHRALDH1A1
SCHEMBL4515148 0.68 CLPP (0.57) CLPPDPP4KMT2ABRD4TSHR
SCHEMBL2898490 0.66 KCNH2 (0.41) CLPPKMT2AALDH1A1NPSR1
SCHEMBL3728938 0.66 P2RX7 (0.74)
SCHEMBL3986391 0.66 NPBWR1 (0.37) CLPPDPP4NOX4KMT2ACOMT
SCHEMBL9741470 0.65 SIRT2 (0.43) CLPPDPP4NOX4COMTBRD4
SCHEMBL2899665 0.65 KCNH2 (0.41) TSHRALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP CLPP 3612/4885DPP4 1882/4885NOX4 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.